mebikar has been researched along with Cognition Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anisimova, TI; Bykova, IuL; Chutko, LS; Iakovenko, EA; Iur'eva, RG; Nikishena, IS; Surushkina, SIu | 1 |
| Marchenko, AA; Puliatkina, OV; Samartsev, IN; Zhivolupov, SA | 1 |
2 trial(s) available for mebikar and Cognition Disorders
| Article | Year |
|---|---|
[Cognitive disturbances in children with anxiety-phobic disorders].
Topics: Adolescent; Anti-Anxiety Agents; Anxiety Disorders; Biureas; Child; Cognition Disorders; Female; Humans; Male; Phobic Disorders; Treatment Outcome | 2011 |
[The prognostic significance of brain-derived neurotrophic factor (BDNF) for phobic anxiety disorders, vegetative and cognitive impairments during conservative treatment including adaptol of some functional and organic diseases of nervous system].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Autonomic Nervous System Diseases; Biureas; Brain-Derived Neurotrophic Factor; Cognition Disorders; Dose-Response Relationship, Drug; Humans; Middle Aged; Phobic Disorders; Prognosis; Treatment Outcome; Young Adult | 2012 |